News From SDEE Members

Arisan Therapeutics (co-PIs Michael Plewe and Ken McCormack) received a two year Advanced Technology Phase I SBIR award (R43AI12097)  in the first quarter of 2014.  

CalAsia Pharmaceuticals, founded by SDEE member Sridhar Prasad  was awarded a $600,000 NIH Phase I SBIR grant to develop novel antiviral agents for the treatment of Dengue (DENV) fever and West Nile Virus (WNV) infection. 

Reveal Biosciences, founded by SDEE member Claire Weston, is offering a new histology service utilizing Advanced Cell Diagnostics’ (ACD) RNAscope® in situ hybridization (ISH) technology.

Christi Norton,  who represents Charles River Laboratories to its regional customers in the West, shared that the company recently acquired Argenta and Biofocus, adding significant early discovery expertise to existing in vivo pharmacology expertise.

Crinetic Pharmaceuticals (founded and led by SDEE member Scott Struthers) was awarded a $2.2 million dollar Phase II Small Business Innovation Research Grant (SBIR) grant from the NIH to develop novel drugs for the treatment of pituitary tumors. 

Reveal Biosciences (founded by SDEE's Claire Weston) signed an agreement with Science Exchange (in partnership with antibodies-online.com) to independently validate commercial antibodies.   The goal of the program is to improve research quality and reduce waste of resources by verifying high quality antibodies.

Orphagen Pharmaceutical was awarded a $446,635 NIH National Center for Advancing Translational Sciences (NCATS) Phase I SBIR grant to Investigate Novel Small Molecules to treat Retina Pigmentosa (RP). SDEE member Scott Thacher, Orphagen's founder and CEO, is a Principal Investigator of the grant. 

Allele Biotechnology (founded by SDEE member Jiwu Wang in 2009) formed clinical partnerships with leaders in pluripotent stem cell therapy that are potentially worth tens of millions of dollars.